LATEST NEWS

TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments

TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.

LATEST FINANCIAL RESULTS

Q2 2017

Quarterly Results, Ended June 30, 2017      

annualReport-10-k

LATEST 10-K

STOCK INFORMATION

TapImmune Inc.

NSDQ: TPIV

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

TapImmune is developing immunotherapies for a variety of cancers that are designed to target both tumors and metastatic disease. The company’s next-generation technology is designed to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells.

IR CONTACT DETAILS

TapImmune

5 West Forsyth St. Suite 200
Jacksonville, FL 32202
T: 866-359-7541
investor.relations@tapimmune.com